Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Global Medical REIT (GMRE-PB) Net Income towards Common Stockholders (2016 - 2025)

Global Medical REIT (GMRE-PB) has disclosed Net Income towards Common Stockholders for 10 consecutive years, with -$7.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income towards Common Stockholders fell 639.88% year-over-year to -$7.4 million, compared with a TTM value of -$12.1 million through Dec 2025, down 1593.96%, and an annual FY2025 reading of -$12.1 million, down 1593.96% over the prior year.
  • Net Income towards Common Stockholders was -$7.4 million for Q4 2025 at Global Medical REIT, down from -$6.0 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $11.8 million in Q2 2023 and bottomed at -$7.4 million in Q4 2025.
  • Average Net Income towards Common Stockholders over 5 years is $1.4 million, with a median of $1.8 million recorded in 2021.
  • The sharpest move saw Net Income towards Common Stockholders surged 1150.98% in 2021, then crashed 639.88% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at $3.8 million in 2021, then plummeted by 90.38% to $366000.0 in 2022, then tumbled by 329.51% to -$840000.0 in 2023, then soared by 263.57% to $1.4 million in 2024, then plummeted by 639.88% to -$7.4 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for GMRE-PB at -$7.4 million in Q4 2025, -$6.0 million in Q3 2025, and -$800000.0 in Q2 2025.